Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.5.1.3 extracted from

  • Eroglu, A.; Egin, Y.; Cam, R.; Akar, N.
    The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis (2008), Ann. Hematol., 88, 73-76.
    View publication on PubMed

Application

Application Comment Organism
medicine the prevalence of dihydrofolate reductase 19-bp deletion polymorphism and of the methylenetetrahydrofolate reductase C677T polymorphism is similar in cancer patients with and without thrombosis. The frequency of factor V Leiden polymorphism is significantly higher in cancer patients with thrombosis. Thus routine screening for dihydrofolate reductase 19-bp deletion polymorphism is not suggested Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
cancer patients with and without thrombosis
-